Λεπτομέρειες βιβλιογραφικής εγγραφής
| Τίτλος: |
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer |
| Συγγραφείς: |
Teo, ZL, O’Connor, MJ, Versaci, S, Clarke, KA, Brown, ER, Percy, LW, Kuykhoven, K, Mintoff, CP, Savas, P, Virassamy, B, Luen, SJ, Byrne, A, Sant, S, Lindeman, GJ, Darcy, PK, Loi, S |
| Στοιχεία εκδότη: |
NATURE PORTFOLIO |
| Έτος έκδοσης: |
2023 |
| Συλλογή: |
The University of Melbourne: Digital Repository |
| Περιγραφή: |
Novel therapeutic strategies that can effectively combine with immunotherapies are needed in the treatment of triple-negative breast cancer (TNBC). We demonstrate that combined PARP and WEE1 inhibition are synergistic in controlling tumour growth in BRCA1/2 wild-type TNBC preclinical models. The PARP inhibitor (PARPi) olaparib combined with the WEE1 inhibitor (WEE1i) adavosertib triggered increases in anti-tumour immune responses, including STING pathway activation. Combinations with a STING agonist resulted in further improved durable tumour regression and significant improvements in survival outcomes in murine tumour models of BRCA1/2 wild-type TNBC. In addition, we have identified baseline tumour-infiltrating lymphocyte (TIL) levels as a potential predictive biomarker of response to PARPi, WEE1i and immunotherapies in BRCA1/2 wild-type TNBC. |
| Τύπος εγγράφου: |
article in journal/newspaper |
| Γλώσσα: |
English |
| ISSN: |
2374-4677 |
| Relation: |
NHMRC/1106967; NHMRC/1136680; https://hdl.handle.net/11343/338785 |
| Διαθεσιμότητα: |
https://hdl.handle.net/11343/338785 |
| Rights: |
https://creativecommons.org/licenses/by/4.0 ; CC BY |
| Αριθμός Καταχώρησης: |
edsbas.9AD4EED1 |
| Βάση Δεδομένων: |
BASE |